GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.
GLORIA is funded by the EU Horizon 2020 Program. >>
This meeting will take place at EULAR (Madrid) on 16th June 2017. An update on trial status is expected and the recruitment efforts will be discussed.
This will be an excellent moment to share the experiences about GLORIA trial which have already recruited patients in seven different countries: Netherlands, Germany, Portugal, Slovakia, Italy, Hungary and Romania.
A presentation of the survey Read more
One of our newst additions to the already fairly extense GLORIAs Document Center is an interesting one:
Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort.
Please click to find an overview of the article, together with a pubmed link!
The next EULAR Annual European Congress of Rheumatology will take place from 14 - 17 June 2017 in Madrid, Spain.
The annual EULAR Congress continues to be a major event for the exchange of scientific and clinical information. It will be a platform to facilitate interactions between patients, medical doctors, scientists, health professionals, and professionals representing the pharmaceutical ind Read more
Feb 2, 2017 - Recent Publications \ News from GLORIA
To describe the perception on the current role of systemic glucocorticoids (GC) in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects.
Systematic literature review using the databases PubMed, EMBASE and Read more